A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice
Open Access
- 26 July 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 112 (1) , 502-514
Abstract
Atherosclerosis is the most common cause of cardiovascular diseases, such as myocardial infarction and stroke. We hypothesized that nagilactone B (NLB), a small molecule extracted from the root bark of Podocarpus nagi (Podocarpaceae), suppresses atherosclerosis in an atherosclerotic mouse model. Male apoE-deficient mice on C57BL/6J background received NLB (10 and 30 mg/kg) for 12 weeks. Compared with the model group, NLB treatment (10 and 30 mg/kg) significantly reduced en face lesions of total aorta areas. In RAW264.7 cells, NLB significantly ameliorated cholesterol accumulation in macrophages via enhancing apolipoprotein A-I and HDL-mediated cholesterol efflux. Mechanistically, NLB induced messenger RNA and protein expression of the ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 and THP-1 cells. Liver X receptor (LXR) site mutations in the mouse ABCA1 promoter abrogated NLB-mediated luciferase reporter activity. LXRα and LXRβ small interfering RNA suppressed NLB-mediated induction of ABCA1 expression. Consistent with in vitro results, NLB induced ABCA1 expression and suppressed macrophage areas in the aortic sinus. Moreover, NLB treatment did not induce the protein expression of LXR in liver. Hepatic and intestinal cholesterol accumulation was significantly alleviated on NLB treatment. Besides, NLB significantly improved plasma lipid profiles in apoE-deficient mice. Selective LXR activation in macrophages with NLB induces ABCA1- and ABCG1-mediated cholesterol efflux while exerting minimal effects on lipogenesis and lipid accumulation in liver, resulting in regression of atherosclerosis, and therefore might be a promising strategy for therapeutics.Keywords
This publication has 49 references indexed in Scilit:
- Liver X Receptor Signaling Pathways and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Inhibition of Glycosphingolipid Synthesis Induces a Profound Reduction of Plasma Cholesterol and Inhibits Atherosclerosis Development in APOE*3 Leiden and Low-Density Lipoprotein Receptor−/− MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice #Hepatology, 2009
- Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoEJournal of Clinical Investigation, 2007
- Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group RecommendationsThe American Journal of Cardiology, 2005
- ABCA1 mediates concurrent cholesterol and phospholipid efflux to apolipoprotein A-IJournal of Lipid Research, 2004
- An antiproliferative norditerpene dilactone, Nagilactone C, fromPhytomedicine, 2001
- Sterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X ReceptorJournal of Biological Chemistry, 2000
- Contribution of cholesterol 7α-hydroxylase to the regulation of lipoprotein metabolismCurrent Opinion in Lipidology, 1999
- Oxidized LDL Binds to CD36 on Human Monocyte-Derived Macrophages and Transfected Cell LinesArteriosclerosis, Thrombosis, and Vascular Biology, 1995